Related Experiment Video

Updated: Mar 8, 2026

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
06:21

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Published on: November 19, 2019

12.3K

Everolimus in Pancreatic Neuroendocrine Carcinomas G3

Francesco Panzuto1, Maria Rinzivillo, Francesca Spada

  • 1From the *Digestive and Liver Diseases, Sant'Andrea Hospital-Sapienza University of Roma, Rome; †Unit of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, Milan; ‡Medical Oncology, Azienda Ospedaliero-Universitaria Careggi, Florence, and Department of Medical Biotechnologies, University of Siena, Siena; §Osteoncology and Rare Tumors Center, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola (FC); and ∥Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.

Pancreas
|January 19, 2017
PubMed
Abstract

Insights

Everolimus shows efficacy in well-moderately differentiated pancreatic neuroendocrine tumors (pNET) G3. This targeted therapy offers disease stabilization and prolonged survival, presenting an alternative to chemotherapy.

Area of Science:

  • Oncology
  • Gastroenterology
  • Pharmacology

Background:

  • Pancreatic neuroendocrine tumors (pNET) G3 are aggressive with limited treatment options.
  • Systemic chemotherapy is the current standard but carries significant toxicity.
  • Everolimus, an mTOR inhibitor, has shown promise in neuroendocrine tumors.

Purpose of the Study:

  • To evaluate the efficacy and safety of everolimus in patients with well-moderately differentiated pancreatic neuroendocrine tumors (pNET) G3.
  • To assess progression-free survival (PFS) and overall survival (OS) in this patient cohort.
  • To determine the potential of everolimus as an alternative treatment for pNET G3.

Main Methods:

  • Retrospective analysis of 15 patients with pNET G3 (Ki67 20%-55%).
  • Patients received everolimus, either as first-line treatment or after prior chemotherapy/PRRT.
  • Evaluation of disease stabilization (DS), PFS, OS, and adverse events.

Main Results:

  • Median PFS was 6 months; median OS was 28 months.
  • Eleven patients (73%) achieved disease stabilization at 3 months.
  • Forty percent of patients maintained DS for at least 12 months; 3 of 4 first-line patients had sustained DS.

Conclusions:

  • Everolimus demonstrates activity in well-moderately differentiated pNET G3 (Ki67 <55%).
  • It offers a potentially less toxic alternative to chemotherapy for this patient population.
  • Further investigation into everolimus for pNET G3 is warranted.

More Related Videos

Robotic Enucleation of an Intra-Pancreatic Insulinoma in the Pancreatic Head05:42

Robotic Enucleation of an Intra-Pancreatic Insulinoma in the Pancreatic Head

Published on: January 3, 2020

8.8K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.3K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
701
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
Pancreas01:19

Pancreas

The pancreas, an essential organ in the human body, is a pinkish-gray elongated structure located posterior to the stomach. It extends laterally from the duodenum towards the spleen and is firmly bound to the posterior wall of the abdominal cavity. The organ's surface has a lumpy, lobular texture that gives it a unique appearance.
The broad head of the pancreas lies within the loop formed by the duodenum, while its slender body reaches towards the spleen. The tail of the pancreas is short...
2.8K